Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Health Data Futures project - 11/01/2024 Eine runde Darstellung der verschiedenen Szenario-Cluster, bei denen farblich markierten Szenarien in den Clustern herausgearbeitet wurden.

    Creating a network of trust

    In the three-nation project "Health Data Futures", stakeholders and experts from Germany, France and Switzerland have launched a series of patient-centred innovations. Using various future scenarios, the project partners may be able to come up with even more scenarios.

    https://biopro-v9-test-gi.xanium.io/en/article/news/creating-network-trust
  • Press release - 08/01/2024

    Brain tumors in children: Cancer cells become less aggressive as they migrate within the tumor

    Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/hirntumoren-bei-kindern-krebszellen-werden-auf-ihrer-wanderung-im-tumor-weniger-aggressiv
  • Press release - 05/01/2024

    Prostate cancer: Newly-developed inhibitor shows massive potential

    More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential
  • Press release - 05/01/2024

    How memories are formed in the brain – a new role for the internal compass

    University of Tübingen neuroscientists discover new functions of head-direction cells suggesting they may contribute to episodic memory formation.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/how-memories-are-formed-brain-new-role-internal-compass
  • Press release - 04/01/2024

    Key player in viral heart inflammation discovered

    Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/key-player-viral-heart-inflammation-discovered
  • Press release - 18/12/2023

    Researchers discover novel antibiotic substance from the human nose

    For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/researchers-discover-novel-antibiotic-substance-human-nose
  • Press release - 08/12/2023

    Where does chronic pain come from?

    Professor Dr. Rohini Kuner from the Medical Faculty of Heidelberg University receives the Leibniz Prize of the German Research Foundation (DFG).

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/woher-kommen-chronische-schmerzen
  • Press release - 30/11/2023

    Taking antibiotics back in time

    University of Tübingen researchers reverse the evolution of a class of antibiotics to gain insights for the development of new drugs.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/taking-antibiotics-back-time
  • Press release - 29/11/2023

    Tracing the Evolution of the Cerebellum

    Heidelberg scientists unveil genetic programmes controlling the development of cellular diversity in the cerebellum of humans and other mammals. The research results have now been published in the journal Nature.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/tracing-evolution-cerebellum
  • Press release - 15/11/2023

    Nanoparticles for optimized cancer therapy

    Pancreatic cancer is one of the deadliest types of cancers in humans. Chemotherapies attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely. The approach was developed by a research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/nanopartikel-fuer-optimierte-krebstherapie
  • Press release - 10/11/2023

    Therapy resistance in multiple myeloma: molecular analyses of individual cancer cells reveal new mechanisms

    All cancer cells - even those within the same tumor - differ from each other and change over the course of a cancer disease. Scientists at Heidelberg University Hospital, the Medical Faculty in Heidelberg and the German Cancer Research Center discovered molecular changes in multiple myeloma that help individual cancer cells to survive therapy.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/therapy-resistance-multiple-myeloma-molecular-analyses-individual-cancer-cells-reveal-new-mechanisms
  • Press release - 06/11/2023

    Improving the efficacy of cancer immunotherapy with modified CAR-T cells

    CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/improving-efficacy-cancer-immunotherapy-modified-car-t-cells
  • Press release - 30/10/2023

    New research group: construction of tissue in laboratory

    An interdisciplinary research group combining mechanical engineering and biotechnology has taken up its work at the Institute for Molecular Systems Engineering and Advanced Materials (IMSEAM) of Heidelberg University. The team under the direction of Dr Kai Melde will pursue an innovative approach to biofabrication – 3D cell culture using ultrasound. Tools are being developed that can be used as an alternative to or enhancement for 3D printing.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/neue-forschungsgruppe-konstruktion-von-gewebe-im-labor
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen
  • Press release - 20/10/2023

    Why tuberculosis bacteria form long chains

    A researcher team from Ecole Polytechnique Federal de Lausanne led by Dr. Vivek Thacker now group leader at the Department of Infectious Diseases at Heidelberg University Hospital have studied why tuberculosis bacteria form long strands and how this affects their infectivity. Their findings could lead to new therapies and have now been published in the journal Cell.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/why-tuberculosis-bacteria-form-long-chains
  • Press release - 04/10/2023

    Therapeutic option for tumor patients with the rare DNAJB1-PRKACA gene fusion

    A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/therapeutic-option-tumor-patients-rare-dnajb1-prkaca-gene-fusion
  • Press release - 21/09/2023

    Mutation-specific peptide vaccine against midline gliomas used in patients for the first time

    Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/mutation-specific-peptide-vaccine-against-midline-gliomas-used-patients-first-time
  • Press release - 19/09/2023

    Better distinguish chronic inflammation and cancer of the pancreas

    Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/chronische-entzuendung-und-krebs-der-bauchspeicheldruese-praeziser-unterscheiden
  • Press release - 28/08/2023

    Innovative computational approach helps design proteins for cancer treatment

    The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/innovative-computational-approach-helps-design-proteins-cancer-treatment
  • Press release - 10/08/2023

    Computer-aided cell analysis for faster diagnosis of blood diseases

    Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples. The algorithm can help physicians diagnose blood disorders and is available as an open source method for research purposes.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/computergestuetzte-zellanalyse-fuer-die-schnellere-diagnose-von-blutkrankheiten
  • Press release - 07/08/2023

    Vegan trend in Europe: In Germany, milk substitutes from plants are most popular alternative

    Germany has the most active market, Southern Europe wants more variety, and people in Poland find dairy substitutes too expensive, according to a recent study by the University of Hohenheim.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/vegan-trend-europe-germany-milk-substitutes-plants-are-most-popular-alternative
  • Press release - 02/08/2023

    Freiburg research team casts light on signal-dependent formation of mitochondria

    Known as the power plant of the cell, mitochondria are essential to human metabolism. Human mitochondria consist of 1,300 different proteins and two fatty biomembranes. The vast majority of mitochondrial proteins are produced with a cleavable transport signal and have to be actively transported into the mitochondria.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/freiburger-forschungsteam-klaert-signalabhaengige-bildung-von-mitochondrien-auf
  • Press release - 20/07/2023

    Animal testing under REACH: bringing numbers into the debate

    So far, 4.2 million animal tests under the REACH chemical regulation: A study from Konstanz and Baltimore quantifies the number of animals that died for the hazard assessment of chemicals in the chemical industry.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/tierversuche-durch-reach-zahlen-die-debatte-bringen
  • Press release - 20/07/2023

    Anal Cancer Screening: New Microbiome-Associated Biomarkers Could Improve Prevention

    A new study published in Nature Medicine, July 2023 has identified two novel markers for screening high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, from the anal microbiome of people with HIV (PWH). PWH are at a significantly higher risk of developing anal cancer. Current screening methods, such as anal cytology, have low specificity for detecting HSIL, which hinders the prevention of anal cancer.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/anal-cancer-screening-new-microbiome-associated-biomarkers-could-improve-prevention

Page 3 / 11

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 11
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://biopro-v9-test-gi.xanium.io/en/search